| Authors: |
Sadda SR; RIMR AMD Consortium, Pasadena, CA, USA. ssadda@doheny.org.; Doheny Eye Institute, 150 North Orange Grove Blvd, Pasadena, CA, 91103, USA. ssadda@doheny.org.; Department of Ophthalmology, University of California - Los Angeles, Los Angeles, CA, USA. ssadda@doheny.org., Wykoff CC; Retina Consultants of Texas, Houston, TX, USA., Chowers I; Hadassah Medical Center, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel., Korobelnik JF; CHU Bordeaux, Service d'ophtalmologie, France.; University of Bordeaux, INSERM, BPH, UMR1219, Bordeaux, F-33000, France., Narayana R; Anant Bajaj Retina Institute, L.V. Prasad Eye Institute, Hyderabad, India., Pappuru RR; Anant Bajaj Retina Institute, L.V. Prasad Eye Institute, Hyderabad, India., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany., Guymer R; Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, The University of Melbourne, Melbourne, Australia., Cheung CMG; Singapore National Eye Center, Singapore, Singapore., Boyer DS; Retina Vitreous Associates, Los Angeles, CA, USA., Ip M; RIMR AMD Consortium, Pasadena, CA, USA.; Doheny Eye Institute, 150 North Orange Grove Blvd, Pasadena, CA, 91103, USA.; Department of Ophthalmology, University of California - Los Angeles, Los Angeles, CA, USA., Niessen HG; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Holenkamp N; Roche Pharmaceuticals, Basel, Switzerland., Durbin M; Topcon Healthcare Inc, Oakland, NJ, USA., Magazzeni S; Carl Zeiss Meditec AG, Munich, Germany., Cairns AM; Optos plc, Dunfermline, Scotland, UK., Ciller C; Ikerian AG, Bern, Switzerland and RetinAI U.S. Inc., Boston, MA, USA., Jovic N; Ikerian AG, Bern, Switzerland and RetinAI U.S. Inc., Boston, MA, USA., Blair J; Ikerian AG, Bern, Switzerland and RetinAI U.S. Inc., Boston, MA, USA., De Zanet S; Ikerian AG, Bern, Switzerland and RetinAI U.S. Inc., Boston, MA, USA., Lee AY; RIMR AMD Consortium, Pasadena, CA, USA.; University of Washington, Seattle, WA, USA. |
